Evidence map›Paper›PMID 28660378›Full record

ArticleEndocrine2018

Mineral metabolism abnormalities in patients with prostate cancer: a systematic case controlled study.

Francesco Minisola, Cristiana Cipriani, Luciano Colangelo, Mirella Cilli, Alessandro Sciarra, Magnus Von Heland, Luciano Nieddu, Emanuela Anastasi, Roberto Pascone, Valeria Fassino and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Controversies Surrounding Vitamin D: Focus on Supplementation and Cancer.International journal of environmental research and public health · 2019
    Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Francesco MinisolaDepartment of Gynecology-Obstetrics & Urology, Sapienza University of Rome, Rome, Italy.
Cristiana CiprianiDepartment of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome, Italy.
Luciano ColangeloDepartment of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome, Italy.
Mirella CilliDepartment of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome, Italy.
Alessandro SciarraDepartment of Gynecology-Obstetrics & Urology, Sapienza University of Rome, Rome, Italy.
Magnus Von HelandDepartment of Gynecology-Obstetrics & Urology, Sapienza University of Rome, Rome, Italy.
Luciano NiedduFaculty of Economics, UNINT University, Via delle Sette Chiese 139, 00147, Rome, Italy.
Emanuela AnastasiDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Roberto PasconeDepartment of Pediatrics and Infantile Neuropsychiatry, Sapienza University of Rome, Rome, Italy.
Valeria Fassino
Daniele DiacintiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Flavia LongoDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Salvatore MinisolaDepartment of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome, Italy. salvatore.minisola@uniroma1.it.
Jessica PepeDepartment of Internal Medicine and Medical Disciplines, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITUniversità degli Studi Internazionali di Roma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProstate cancer is the most common tumor in men. To the best of our knowledge a systematic assessment of bone and mineral abnormalities has not been performed in prostatic cancer patients consecutively enrolled.

methodsThis study was therefore carried out to investigate changes of skeletal and mineral metabolism in patients with prostate cancer (n  = 69). A population of patients with cancer of various origin was also investigated as a control group (n  = 53), since a comparison with non-prostate cancer patients has not been previously reported.

resultsIn the prostatic cancer group, one patient had extremely high values of C-terminal Fibroblast Growth Factor 23, low values of tubular reabsorption of phosphate and very high values of bone alkaline phosphatase, suggesting the diagnosis of oncogenic osteomalacia. We found nine patients with primary hyperparathyroidism in the group of prostate cancer vs. only one in cancer patients group (p  <  0.026). We stratified the population on the basis of Gleason score, prostate specific antigen and hormonal therapy. Using a generalized linear model with a logit link to predict the probability of developing primary hyperparathyroidism, only Gleason score, C-terminal fibroblast growth factor 23 and hormonal therapy had a significant effect (p  < 0.05). Controlling for other covariates, a rise in fibroblast growth factor 23 increases the odds of developing primary hyperparathyroidism by 2% (p  = 0.017), while patients with higher values of Gleason score have a much greater probability of developing primary hyperparathyroidism (log-odds  =  3.6, p  <  0.01). The probability decreases with higher values of Gleason score while on hormonal therapy; a further decrease was observed in patients on hormonal treatment and lower values of GS. Finally, lower grade of Gleason score without hormonal therapy have a significant protective factor (p  <  0.01) decreasing the odds of developing primary hyperparathyroidism by 8%.

conclusionWe showed a remarkable prevalence of primary hyperparathyroidism in men with prostate cancer; the multivariate analysis demonstrates that higher aggressiveness of prostate cancer, as determined by Gleason score, is a significant predictor of increased risk of developing primary hyperparathyroidism.

Indexed as

AgedAlkaline PhosphataseCase-Control StudiesFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMaleMiddle AgedNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsVitamin DAlkaline PhosphataseFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsProstate-Specific AntigenVitamin DFGF23HypercalcemiaHyperparathyroidismProstate cancerVitamin D

Identifiers

PMID28660378
OpenAlexW2726409463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.